Barbara Sarholz
Research Subjects
Barbara Sarholz has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Almudena Rodriguez-Gutierrez
Merck, S.L.U., Madrid, Spain, an affiliate of Merck KGaA, Darmstadt, Germany
27 shared publications - Andreas Becker
Translational Medicine, Quantitative Pharmacology, the Healthcare Business of Merck KGaA, Darmstadt, Germany
27 shared publications - Anna Coenen-Stass
The Health Care Business of Merck KGaA, Darmstadt, Germany
27 shared publications - Carlos Fernandez Martos
Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain
27 shared publications - Eric D. Miller
Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH (E.D.M.).
27 shared publications - Jaume Capdevila
Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)
27 shared publications
Latest Publications
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Late toxicities by worst Grade (≥3) and System Organ Class
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Late toxicities by worst Grade (≥3) and System Organ Class
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Frequency of pathogenic/likely pathogenic loss-of-function mutation(s) in TP53, ATM and other CRC relevant genes and MSS/MSI status
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Frequency of pathogenic/likely pathogenic loss-of-function mutation(s) in TP53, ATM and other CRC relevant genes and MSS/MSI status
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Late toxicities by worst Grade (≥3) and System Organ Class
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Late toxicities by worst Grade (≥3) and System Organ Class
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
. pDNA-PK/tDNA-PK ratios in PBMCs stimulated with bleomycin, pre- and post-dosing with peposertib.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
. pDNA-PK/tDNA-PK ratios in PBMCs stimulated with bleomycin, pre- and post-dosing with peposertib.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Data from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Purpose:Peposertib—an orally administered DNA-dependent protein kinase inhibitor—has shown potent radiosensitization in preclinical models. This dose-escalation study (NCT03770689) aimed to define the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of peposertib plus capecitabine-based chemoradiotherapy (CRT) and assessed its safety and efficacy in locally advanced rectal cancer.Patients and Methods:Patients were treated for 5 to 5.5 weeks with 50- to 250-mg peposertib once daily, capecitabine 825 mg/m2 twice daily, and radiotherapy (RT), 5 days per week. Following clinical restaging (8 weeks after CRT completion), patients with clinical complete response (cCR) could opt for surveillance. Total mesorectal excision was recommended upon incomplete response (IR).Results:Nineteen patients were treated with peposertib at doses of 50 mg (n = 1), 100 mg, 150 mg, and 250 mg (n = 6 each). Dose-limiting toxicities occurred in one out of five (100 mg), one out of six (150 mg), and three out of six (250 mg) evaluable patients. Peposertib ≤150 mg once daily was tolerable in combination with CRT. After 8 weeks of treatment with peposertib and CRT, the cCR was 15.8% (n = 3). Among the three patients with cCR, two underwent surgery and had residual tumors. Among the 16 patients with IR, seven underwent surgery and had residual tumors; five of the remaining nine patients opted for consolidative chemotherapy. The combined cCR/pathologic complete response (pCR) rate was 5.3% (n = 1, 100 mg cohort).Conclusions:Peposertib did not improve complete response rates at tolerable dose levels. The study was closed without declaring the MTD/RP2D.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Purpose:Peposertib—an orally administered DNA-dependent protein kinase inhibitor—has shown potent radiosensitization in preclinical models. This dose-escalation study (NCT03770689) aimed to define the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of peposertib plus capecitabine-based chemoradiotherapy (CRT) and assessed its safety and efficacy in locally advanced rectal cancer.Patients and Methods:Patients were treated for 5 to 5.5 weeks with 50- to 250-mg peposertib once daily, capecitabine 825 mg/m2 twice daily, and radiotherapy (RT), 5 days per week. Following clinical restaging (8 weeks after CRT completion), patients with clinical complete response (cCR) could opt for surveillance. Total mesorectal excision was recommended upon incomplete response (IR).Results:Nineteen patients were treated with peposertib at doses of 50 mg (n = 1), 100 mg, 150 mg, and 250 mg (n = 6 each). Dose-limiting toxicities occurred in one out of five (100 mg), one out of six (150 mg), and three out of six (250 mg) evaluable patients. Peposertib ≤150 mg once daily was tolerable in combination with CRT. After 8 weeks of treatment with peposertib and CRT, the cCR was 15.8% (n = 3). Among the three patients with cCR, two underwent surgery and had residual tumors. Among the 16 patients with IR, seven underwent surgery and had residual tumors; five of the remaining nine patients opted for consolidative chemotherapy. The combined cCR/pathologic complete response (pCR) rate was 5.3% (n = 1, 100 mg cohort).Conclusions:Peposertib did not improve complete response rates at tolerable dose levels. The study was closed without declaring the MTD/RP2D.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
. pDNA-PK/tDNA-PK ratios in PBMCs stimulated with bleomycin, pre- and post-dosing with peposertib.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
. pDNA-PK/tDNA-PK ratios in PBMCs stimulated with bleomycin, pre- and post-dosing with peposertib.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Frequency of pathogenic/likely pathogenic loss-of-function mutation(s) in TP53, ATM and other CRC relevant genes and MSS/MSI status
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Frequency of pathogenic/likely pathogenic loss-of-function mutation(s) in TP53, ATM and other CRC relevant genes and MSS/MSI status
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Kaplan-Meier curve of disease-free survival
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Kaplan-Meier curve of disease-free survival